Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data

PHASE3CompletedINTERVENTIONAL
Enrollment

2,977

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

March 21, 2025

Study Completion Date

March 21, 2025

Conditions
Perioperative Optimization
Interventions
DRUG

Neuraxial Analgesia

This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).

DRUG

Regional Block 1: Paravertebral

This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)

DRUG

Perphenazine

This randomized group will receive 8 mg of perphenazine orally preoperatively.

DRUG

Aprepitant

This randomized group will receive 40 mg of aprepitant orally preoperatively.

DRUG

Dimenhydrinate

This randomized group will receive 25 mg of dimenhydrinate orally preoperatively.

DRUG

Ondansetron 4 MG

This randomized group will receive 4 mg of ondansetron orally.

DRUG

Dexamethasone

This randomized group will receive 4-5 mg of dexamethasone intravenously.

DRUG

Regional Block 2: QL1

This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)

Trial Locations (3)

15213

UPMC Magee-Womens Hospital, Pittsburgh

UPMC Presbyterian, Pittsburgh

15237

UPMC Passavant, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Berry Consultants

OTHER

lead

Jennifer Holder-Murray

OTHER